NASDAQ$ALT
Altimmune Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Altimmune's financial position detailed for Q2 2023, with ongoing clinical trials and financial results reported.
Altimmune reported a net loss of $16.1 million, or $0.32 per share, for the second quarter of 2023. The company's research and development expenses were $13.3 million, and general and administrative expenses were $4.8 million. As of June 30, 2023, Altimmune had cash, cash equivalents, and short-term investments totaling $160.0 million. They also commenced enrollment in the IMPACT Phase 2b trial of pemvidutide in NASH, and top-line results from the MOMENTUM Phase 2 obesity trial are expected in Q4 2023.
- Commenced enrollment in IMPACT Phase 2b trial of pemvidutide in NASH.
- Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023.
- Top-line results from the Phase 2 trial of HepTcellTM in chronic hepatitis B (CHB) expected Q1 2024.
- Cash, cash equivalents and short-term investments totaled $160.0 million as of June 30, 2023.
Headline financials
Revenue & EPS history
Altimmune · Revenue · Quarterly
$6K
Forward guidance
The company is focused on advancing its clinical programs, with key data readouts expected in the coming quarters for pemvidutide and HepTcell.
Tailwinds
- Top-line data readout from 48-week MOMENTUM Phase 2 obesity trial expected in Q4 2023.
- Commenced enrollment in IMPACT Phase 2b NASH trial.
- Top-line data from Phase 2 clinical trial of HepTcell expected in Q1 2024.
- Pemvidutide incorporates the EuPortTM domain, a proprietary technology that increases its serum half-life for weekly dosing while likely slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability.
- Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Headwinds
- Forward-looking statements are subject to numerous assumptions, risks, and uncertainties.
- Delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy.
- The reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates.
- The Company’s ability to manufacture clinical trial materials on the timelines anticipated.
- The success of future product advancements, including the success of future clinical trials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+2.4%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+5.6%
Avg return
30 days after
60%
21 / 35 earnings
Positive
+35.0%
Q2 2022
Best reaction
-25.1%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -8.8% | -15.3% | |
| Q4 2025 | -17.6% | -9.6% | -21.8% | |
| Q3 2025 | +5.1% | +14.1% | +39.7% | |
| Q1 2025 | -4.2% | -7.2% | +19.0% | |
| Q4 2024 | +8.1% | +0.3% | -10.4% | |
| Q3 2024 | +29.5% | +3.5% | +16.9% | |
| Q2 2024 | +12.2% | +14.7% | +12.7% | |
| Q1 2024 | +0.8% | +9.2% | -9.8% | |
| Q4 2023 | +17.7% | +18.3% | -16.1% | |
| Q3 2023 | +1.1% | -6.4% | +146.4% | |
| Q2 2023 | +2.0% | -4.7% | -16.9% | |
| Q1 2023 | +2.2% | -6.6% | -19.7% | |
| Q4 2022 | +1.9% | -2.0% | -64.3% | |
| Q3 2022 | +10.3% | +12.7% | +4.2% | |
| Q2 2022 | +35.0% | +37.3% | +55.4% | |
| Q1 2022 | +31.0% | +34.3% | +117.0% | |
| Q4 2021 | +2.2% | +12.1% | -18.7% | |
| Q3 2021 | -0.5% | +1.3% | -12.3% | |
| Q2 2021 | +6.6% | +14.9% | +56.8% | |
| Q1 2021 | +5.2% | +4.7% | +23.0% | |
| Q4 2020 | -18.6% | -19.5% | -29.3% | |
| Q3 2020 | -25.1% | -18.6% | -1.1% | |
| Q2 2020 | -13.5% | -5.5% | -54.3% | |
| Q1 2020 | +21.4% | +21.6% | +103.8% | |
| Q4 2019 | -7.1% | -6.5% | -2.8% | |
| Q3 2019 | -8.0% | -10.9% | -1.7% | |
| Q2 2019 | -6.5% | -6.5% | -0.9% | |
| Q1 2019 | +2.7% | -4.7% | -3.5% | |
| Q4 2018 | +3.4% | +6.6% | -0.7% | |
| Q3 2018 | -6.8% | -9.1% | -31.5% | |
| Q2 2018 | +4.9% | +0.3% | -21.0% | |
| Q1 2018 | +10.8% | -1.9% | +1.7% | |
| Q4 2017 | -8.3% | -5.9% | -36.0% | |
| Q3 2017 | -1.0% | -7.1% | -25.1% | |
| Q2 2017 | -10.3% | -12.0% | +11.6% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro